Molsidomin-LF tablets 2 mg №10×3

Name:
Molsidomine-LF tab.2mg in a cell. pack No. 10×3
Description:
Round tablets of white or almost white color of a flat-cylindrical shape with a chamfer, a risk on one side. The dividing line is intended for breaking the tablet in order to facilitate swallowing, it is not intended for dividing the tablet into doses. The main active ingredient Molsidomin Release form Tablets. Dosage 2 mg It is necessary to individually approach the dosage of the drug in patients with a high risk of developing arterial hypotension. In the acute period of myocardial infarction, the drug can be used only after stabilization of hemodynamic parameters. In renal failure, the concentration of molsidomine in the blood plasma does not change. The drug Molsidomin-LF can be combined with other antianginal agents (for example, added to two- or three-component treatment – nitrates, slow calcium channel blockers and beta-adrenergic receptor blockers). In case of impaired liver function, only with a pronounced decrease in it (increase in bromsulfalein test up to 20-50%), the concentration of molsidomine in the blood plasma and the half-life increase, which may require adjustment of the dose of the drug. During treatment, alcohol should be excluded. This medicinal product contains lactose monohydrate and should not be used in patients with rare hereditary disorders of galactose intolerance, hereditary lactase deficiency or glucose-galactose malabsorption syndrome. Indications for use Prevention of angina attacks; Chronic heart failure (as part of combination therapy with cardiac glycosides, diuretics). Dosage and administration Tablets should be taken during or after meals with a sufficient amount of liquid (1/2 cup). The drug Molsidomin-LF is taken at regular intervals. The dose of the drug depends on the severity of the disease, and the patient’s response to treatment. At the beginning of treatment, 2 mg is prescribed (1 tablet Molsidomine – LF with a dosage of 2 mg) – 2 times a day (4 mg molsidomine). Maintenance therapy is usually: 4 mg (2 tablets Molsidomine – LF 2 mg or 1 tablet Molsidomine – LF tablet 4 mg) 2 times a day (8 mg molsidomine). In some cases, 2 mg is prescribed (1 tablet Molsidomine – LF with a dosage of 2 mg) 2-3 times a day (4 to 6 mg molsidomine). In severe cases – 4 mg (2 tablets Molsidomine – LF with a dosage of 2 mg or 1 tablet Molsidomine – LF tablet with a dosage of 4 mg) 3-4 times a day (12-16 mg of molsidomine). Elderly people with hepatic or renal insufficiency should use lower doses, set individually. Use during pregnancy and lactation The drug is not used during pregnancy. If it is necessary to prescribe the drug during lactation, breastfeeding should be abandoned. Influence on the ability to drive vehicles and control mechanisms During the period of treatment (especially at the beginning), it is necessary to refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Interaction with other drugs With the simultaneous appointment of Molsidomine-LF with peripheral vasodilators, blockers of “slow” calcium channels, antihypertensive drugs and ethanol, the hypotensive effect is enhanced. Simultaneous administration of the drug with acetylsalicylic acid enhances antiplatelet activity. There is an increased risk of developing arterial hypotension while taking phosphodiesterase 5 (PDE 5) inhibitors, such as sildenafil, tadalafil, vardenafil. The combined use of PDE 5 with molsidomine is contraindicated. There is an increased risk of developing arterial hypotension while taking molsidomine and sapropterin. Contraindications Hypersensitivity to molsidomine or any of the components of the drug; Acute circulatory failure (shock, collapse); Low filling pressure of the left ventricle in acute myocardial infarction and left ventricular failure; Severe arterial hypotension (systolic blood pressure less than 100 mm Hg); Pregnancy and the period of breastfeeding; Simultaneous use of phosphodiesterase type 5 inhibitors (PDE 5) – sildenafil, tadalafil, vardenafil – due to a high risk of arterial hypotension; Age up to 18 years; Lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (due to with the fact that the preparation contains lactose monohydrate). obstructive o cardiomyopathy, constrictive pericarditis, cardiac tamponade, aortic and mitral stenosis. Composition 1 tablet contains: Active substance: molsidomine – 2 mg. Excipients: magnesium stearate, crospovidone, lactose monohydrate. Overdose When taking a large amount of the drug, the following symptoms may occur: severe headache, marked decrease in blood pressure, tachycardia. Treatment: vomiting should be provoked, gastric lavage should be carried out, symptomatic therapy should be applied. Side effect The frequency of adverse reactions indicated below was determined using the following note: very often (> 1/10), often (> 1/100 – < 1/10), infrequently (> 1/1.000 – < 1/100), rarely (> 1/10.000 – < 1/1.000), very rare (< 1/10.000), not known (cannot be determined from the available data). Nervous system disorders: at the beginning of treatment, sometimes - headache; rarely - dizziness, fatigue, slowing down the speed of psychomotor reactions. Gastrointestinal disorders: rarely - nausea, loss of appetite, diarrhea. From the side of the cardiovascular system: often - a pronounced decrease in blood pressure, sometimes up to collapse, rarely - tachycardia, orthostatic hypotension, reddening of the skin of the face. Immune system disorders: rarely - allergic reactions (skin rash, itching, bronchospasm), with an unknown frequency - the development of anaphylactic shock. Blood and lymphatic system disorders: thrombocytopenia. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25? Keep out of the reach of children. Buy Molsidomin-LF tablets 2 mg No. 10x3 Price for Molsidomin-LF tablets 2 mg No. 10x3